Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Neuralstem has obtained notice of allowance for a patent that covers various methods to use expanded spinal cord stem cells such as NSI-566 to treat amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease).
Subscribe to our email newsletter
The company completed Phase I safety trial of NSI-566 stem cells in ALS and also won orphan drug designation.
Upon FDA approval, a Phase II trial is scheduled for commencement.
Neuralstem chairman and chief scientific officer Karl Johe said the previous claims cover methods of culturing and treating neurodegenerative conditions uisng NSI-566 cells
"The claims being allowed here cover methods for using these cells specifically in the treatment of ALS, an indication in which we have already reported peer-reviewed patient data and anticipate advancing to a Phase II study soon," Johe added.